Investors

Download Presentation

Investment Highlights

We are a preclinical-stage oncology company leading the development of Polynucleotide Kinase Phosphatase (PNKP) Novel Target for the Next-Generation in DNA Damage Response Inhibition

Market Size

• DNA Damage Response (DDR) Inhibitors (DDRi) represented an approximate 6.8 - 7B range in sales in 2025 (¹) • We are aware of no clinical-stage PNKP inhibitor program. Onco is well positioned to advance PNKP inhibition to a First-in-Human trial.

Market Size

• DNA Damage Response (DDR) Inhibitors (DDRi) represented with more than $7B in sales in 2025 (1). • PNKP inhibitors (PNKPi) is emerging as a unique new DDRi class and ONCO is well positioned as its leader.

Mechanism of Action

• PNKP is central to repairing DNA strand breaks and damaged DNA bases. • PNKPi sensitizes cancers to DNA damaging agents and exploits common synthetic lethal partners

Mechanism of Action

• PNKP is central to repairing DNA strand breaks and damaged DNA bases. • PNKPi sensitizes cancers to DNA damaging agents and exploits common synthetic lethal partners

Lead Program

• Favourable tolerability observed in early animal studies; IND-enabling GLP toxicology is ongoing. • Advancing toward clinical translation in mid-2027, subject to regulatory approval, GMP supply and final protocol.

Lead Program

Intellectual Property

• Exclusive worldwide rights to the University of Alberta's foundational PNKP-inhibitor patent estate for oncology applications.

Intellectual Property

• Exclusive worldwide rights to the University of Alberta's foundational PNKP-inhibitor patent estate for oncology applications.

AI-native Accelerated Approach

• Leveraging PNKPi specific data & models to reduce the time, cost and risk of clinical efforts & expand our IP & pipeline

View Press Release

AI-native Accelerated Approach

• Leveraging PNKPi specific data & models to reduce the time, cost and risk of clinical efforts & expand our IP & pipeline

View Press Release

Onco-Innovations Stock Performance

CBOE: ONCO

FWB: W1H

OTCQB: ONNVF

Sedar Filings

Visit SEDAR+ to search the updated System for Electronic Document Analysis and Retrieval to view company documents

Sedar Filings

Onco Notice 2025

Onco Proxy 2025

Onco Return Card

Onco Management Circular 2025

Annual Information Form

Consolidated Financial Statements

Management Discussion and Analysis

ONCO LIFE OFFERING

References

Footnote 1: Future Market Insights, PARP Inhibitors Market, 2026. Global Industry Analysts, Inc., DNA Repair Drugs — Global Strategic Business Report, July 2026, distributed by ResearchAndMarkets.com (report 6071261)."

Onco-Innovations pioneers cancer research, developing

cutting-edge therapies to treat cancer.